Labcorp stock falls as CMS cuts challenge its growth outlook

Published on 09/23/2026 at 10:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Labcorp stock closed at USD 320.71 on September 21, 2026, after CMS proposed reimbursement cuts of up to 15 percent. Fiscal 2026 EPS guidance is USD 18.10 to USD 18.55.

Aquarellbild eines gläsernen Bürogebäudes vor Skyline in Pastelltönen — Aquarellmalerei einer Stadtlandschaft mit gläsernem Firmensitz symbolisiert Labcorp, ISIN US50540R4092, im Gesundheitssektor, Illustration mit AI erstellt.

Labcorp (ISIN US50540R4092) closed at USD 320.71 on the NYSE on September 21, 2026, down 0.63 percent from the prior session. The immediate pressure came from preliminary Medicare reimbursement rates that could reduce laboratory payments by up to 15 percent for 2027 through 2029, while the company kept its longer-term growth framework intact.

CMS cuts create a policy risk

According to Ad-hoc-News on September 22, 2026, Truist Securities lifted its Labcorp price target from USD 350 to USD 365 while keeping a Buy rating. The same report said Labcorp raised its adjusted fiscal 2026 EPS range to USD 18.10 to USD 18.55, with the midpoint increasing from USD 18.00 to USD 18.30.

The policy issue is material because the proposed rates affect a core reimbursement channel. A separate report from The Motley Fool on September 22, 2026, said Labcorp stock was down 3.3 percent during morning trading after CMS disclosed that Medicare had been paying about 16 percent more for laboratory work than private insurers.

Growth targets remain unchanged

Labcorp reaffirmed a 2026 to 2029 framework that calls for compound annual revenue growth of 5 percent to 8 percent, adjusted operating margin expansion of 75 to 150 basis points by the end of 2029, and adjusted EPS growth of 8.5 percent to 11.5 percent. Those figures were reported by StockTitan on September 22, 2026.

The latest quarterly figures provide a second reference point. Labcorp reported adjusted earnings of USD 4.99 per share and revenue of USD 3.73 billion for the quarter ended June 30, 2026, beating consensus EPS of USD 4.78 and revenue of USD 3.71 billion. Revenue was 5.8 percent higher than in the year-earlier quarter, when adjusted EPS was USD 4.35, according to MarketBeat on September 22, 2026.

Stock remains below yearly high

The September 21 close stood within a 52-week range of USD 244.52 to USD 341.80. That left the stock USD 21.09 below the high and USD 76.19 above the low, while a September 22 market snapshot placed Labcorp's market capitalization at USD 26.05 billion and its 200-day simple moving average at USD 283.41.

For investors, the central calculation is the gap between operating growth and reimbursement pressure. Labcorp's 5 percent to 8 percent long-term revenue range and its 8.5 percent to 11.5 percent adjusted EPS range remain higher than zero, but the proposed 15 percent payment reduction introduces a concrete regulatory variable for future margins.

Labcorp stock closes at USD 320.71

Labcorp stock closed at USD 320.71 on the NYSE on September 21, 2026, down 0.63 percent from the prior session. The USD 26.05 billion market capitalization was reported as of September 22, 2026.